FDG PET for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers (Replaced with Section 220.6.17) - RETIRED | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its FDG PET coverage policy for brain, cervical, ovarian, pancreatic, small cell lung, and testicular cancers, retiring the prior policy and replacing it with Section 220.6.17, effective May 15, 2026. Here's what billing teams need to do.

This retirement isn't a minor tweak. CMS is folding FDG PET cancer coverage into a consolidated NCD framework under Section 220.6.17. If your practice or facility bills FDG PET scans for any of these six cancer types under Medicare, your billing guidelines and documentation workflows need to reflect the new section reference before the effective date of May 15, 2026. The policy does not list specific codes in the available data—but the clinical scope makes clear this touches oncology PET billing broadly.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS / Medicare
Policy	FDG PET for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers — RETIRED, replaced by Section 220.6.17
Policy Code	N/A
Change Type	Modified (Retirement + Replacement)
Effective Date	May 15, 2026
Impact Level	High
Specialties Affected	Oncology, Nuclear Medicine, Radiology, Radiation Oncology, Gynecologic Oncology, Thoracic Surgery
Key Action	Update all internal policy references, payer correspondence templates, and denial appeal language to cite Section 220.6.17 before May 15, 2026

---

CMS FDG PET Coverage Criteria and Medical Necessity Requirements 2026

The Centers for Medicare & Medicaid Services is retiring its standalone FDG PET coverage policy for six specific cancer types. Those cancers are brain, cervical, ovarian, pancreatic, small cell lung, and testicular. Coverage for these indications moves into Section 220.6.17 of the Medicare National Coverage Determinations manual.

The real issue here is structural. CMS has been consolidating fragmented PET coverage policies into unified NCD sections for several years. This follows the same pattern. The old standalone policy had its own section reference, and any denial appeal or prior authorization request that cited that section reference now needs to cite 220.6.17 instead.

Medical necessity criteria for FDG PET under these cancer types don't disappear with the retirement. They transfer. What changes is where those criteria live and what section number governs them. Your billing team and your compliance officer both need to understand that distinction—this isn't a coverage expansion or restriction, it's a reorganization with real administrative consequences if you miss it.

CMS FDG PET coverage policy under the new Section 220.6.17 framework governs when Medicare will reimburse FDG PET scans for oncologic indications. Medical necessity documentation requirements carry over. If your team has been building prior authorization packages or appeal letters that reference the retired section, those documents need to be updated now—not after a claim denial forces the issue.

Whether FDG PET is covered under Medicare for a specific cancer type still depends on the clinical indication, the stage of workup, and how the ordering physician documents medical necessity. Section 220.6.17 governs those determinations. Pull that section directly from the CMS NCD manual and make sure your team is reading the current version.

---

CMS FDG PET Exclusions and Non-Covered Indications

The retired policy covered six cancer types. The transition to Section 220.6.17 doesn't automatically expand or restrict that list—but billing teams should not assume the criteria are identical in every detail.

FDG PET for indications outside the scope of NCD coverage—certain initial staging contexts for some cancer types, or screening uses—remains non-covered under Medicare. That hasn't changed. What changes is the governing section reference.

If your practice has historically billed FDG PET for testicular or small cell lung cancer and received denials, the denial reason code and the appeal pathway now point to 220.6.17. Update your appeal templates accordingly before May 15, 2026.

---

Coverage Indications at a Glance

The policy data available does not include a granular, indication-by-indication breakdown with coverage status codes. The table below reflects the six cancer types named in the retiring policy title and their general coverage framework as transitioned to Section 220.6.17.

FDG PET for indications beyond these six cancer types may fall under other NCD sections or local coverage determinations issued by your Medicare Administrative Contractor. Check your MAC's LCD library if you're billing PET for cancer types not listed here.

---

CMS FDG PET Billing Guidelines and Action Items 2026

Act on these steps before May 15, 2026. That's not a soft deadline—it's the effective date when the old policy section is no longer the governing reference.

Copy Action Items

If you're not sure how this retirement interacts with your specific payer mix—especially if you have Medicare Advantage contracts that reference the CMS NCD for FDG PET—talk to your billing consultant or compliance officer before May 15.

---

CPT, HCPCS, and ICD-10 Codes for FDG PET Under This Policy Change

The policy data provided does not list specific CPT, HCPCS, or ICD-10 codes. Do not assume this means codes are unaffected.

FDG PET billing typically involves CPT codes for PET imaging and radiopharmaceutical administration. The specific codes applicable to these six cancer types are governed by Section 220.6.17 of the NCD manual. Pull that section directly from CMS to get the current, authoritative code-level guidance.

Do not rely on any internal code list tied to the retired policy as your final reference. Verify codes against Section 220.6.17 before your next claim submission for these cancer types.

If you need code-level detail for FDG PET oncology billing, your MAC's website and the CMS NCD manual are the authoritative sources. PayerPolicy will update this post when CMS publishes the full Section 220.6.17 code-level data.

---

Why This Retirement Matters More Than It Looks

Policy retirements feel administrative. They are—until a claim denial cites an outdated section reference and your appeal fails on a technicality.

The real risk here is documentation and appeal language that still points to the retired section after May 15, 2026. A denial appeal that cites a retired NCD section looks sloppy to a contractor reviewer. Worse, it can slow resolution and affect reimbursement timing on high-dollar oncology claims.

FDG PET scans for cancer indications carry significant reimbursement value. These aren't low-dollar services. A denied or delayed PET claim for pancreatic or ovarian cancer staging is a meaningful revenue cycle event. The administrative fix—updating your section references—is simple. The cost of not doing it is not.

CMS has been consolidating its NCD framework for PET imaging for years. Section 220.6.17 is the destination for oncologic FDG PET coverage policy under Medicare going forward. Get your team aligned to that section now, while you have time before the effective date.

---